2-chloro-3-isopropylimidazo[1,2-α]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 2-chloro-3-isopropylimidazo[1,2-α]pyridine
• 英文别名: 2-Chloro-3-propan-2-ylimidazo[1,2-a]pyridine；2-chloro-3-propan-2-ylimidazo[1,2-a]pyridine
• 化学式: C₁₀H₁₁ClN₂
• 分子量: 194.664
• InChiKey: ZJKQUJVIUPVXBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-氨基吡啶 、 异戊酸 在 氯化亚砜 、 三乙胺 作用下， 以 氯仿 为溶剂， 反应 8.0h， 以81%的产率得到2-chloro-3-isopropylimidazo[1,2-α]pyridine
  参考文献：
  名称：

  胺与羧酸的无过渡金属串联氯环化反应：获得氯咪唑并[1,2-α]吡啶

  摘要：

  报道了2-氨基吡啶与脂肪族羧酸的有效的一锅且无过渡金属的氯环化级联。这种转化为2-氯或3-氯取代的咪唑并[1，2-α]吡啶提供了一种新颖的方法，具有广泛的底物范围。

  DOI：

  10.1021/acs.orglett.5b01868

文献信息

• PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS
  申请人：Gilead Sciences, Inc.

  公开号：US20130164280A1

  公开（公告）日：2013-06-27

  The invention provides compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections. The compounds and compositions are useful for treating Pneumovirinae virus infection including Human respiratory syncytial virus infections.

  该发明提供了用于治疗病毒感染的化合物、药物可接受的盐和酯以及它们的组合物。这些化合物和组合物对于治疗包括人类呼吸道合胞病毒感染在内的肺病毒亚科病毒感染是有用的。
• Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10221146B2

  公开（公告）日：2019-03-05

  The invention provides certain bicyclic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.

  本发明提供了某些式（I）的双环杂环化合物或其药学上可接受的盐，其中X1、X2、R1、R2、R3、R4和Cy如本文所定义。本发明还提供了包含这类式(I)化合物或其药学上可接受的盐的药物组合物，以及使用式(I)化合物或其药学上可接受的盐或包含它们的药物组合物治疗由RORgammaT介导的疾病或病症的方法。
• TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20160304476A1

  公开（公告）日：2016-10-20

  The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , R 1 , R 2 , R 3 , R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
• 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20160304505A1

  公开（公告）日：2016-10-20

  The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R a , R b , R c , R d , R g , and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
• CARBAMATE BENZOXAZINE PROPIONIC ACIDS AND ACID DERIVATIVES FOR MODULATION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20160311787A1

  公开（公告）日：2016-10-27

  The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof wherein R 1 , R 2 , R a1 , R a2 , R b1 , R b2 , R c , R d , and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.